Invo Fertility, Inc. · NASDAQ:IVF
Invo Fertility — Investor Presentation (June 2026)
27 slides from Invo Fertility's investor presentation, June 2026
Slide 1: Life Begins Within – June 2026 Corporate Presentation
L IF E B E G IN S W IT H IN JU N E 2 0 2 6 C O R P O R A T E P R E S E N TA T IO N N A S D A Q : IV F
Slide 2: Forward-Looking Statements
NASDAQ: IVF F O R W A R D -LO O K IN G S T A T E M E N T S This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements made in this presentation t
Slide 3: Our Mission
O U R M IS S IO N We are a healthcare fertility company focused on making advanced fertility care effective, accessible, and empowering for all, through a patient- centered approach that is powered by innovation, compassion and an exceptional team. 3
Slide 4: Company Evolution: Expanding Our Focus in the Fertility Market
NASDAQ: IVF C O M PA N Y E V O LU T IO N E X PA N D IN G O U R F O C U S IN T H E F E R T IL IT Y M A R K E T Beyond our device heritage to a comprehensive healthcare provider + Need different image – to say Fertility center – rather than invocenter Pro p rie tary and no ve l inno vative m e d ic al
Slide 5: Why Now: An Inflection Point
NASDAQ: IVF WHY NO W A N IN F L E C T IO N P O IN T STRUCTURAL O P E R A T IO N A L Im p ro ve d c a p ita l struc ture M & A e x e c utio n w ith a d isc ip line d , a c c re tive a p p ro a c h • All Series C-2 preferred converted or retired and warrant liabilities eliminated; the • Acquisition cr
Slide 6: Fertility Centers
NASDAQ: IVF F E R T IL IT Y C E N T E R S
Slide 7: U.S. IVF Market: Scale, Growth + Consolidation Tailwinds
NASDAQ: IVF F E R T IL IT Y M a rke t U .S . IV F M A R K E T : U.S. ART Clinics by Ownership Type 3 S C A L E , G R O W T H + C O N S O L ID A T IO N T A ILW IN D S 114 • M arke t siz e & g ro w th (U .S . IV F ) 1 (2 0 2 3 ) 197 • ~$5.7B • Est 5.1% CAGR (2024–2030) • C linic land sc ap e (U .S .)
Slide 8: Mission and Growth Strategy
NASDAQ: IVF M IS S IO N A N D G R O W T H S T R A T E G Y B E C O M E A L E A D IN G P R O V ID E R O F F E R T IL IT Y S E R V IC E S A N D T E C H N O LO G Y A c q uisitio ns b ring ac c e le rate d b ulk to o p e ratio ns and faste r p athw ay to o ve rall p ro fitab ility. Setting the company up
Slide 9: Fertility Centers: 1000+ Cycles in 2025 Across 4 Centers
NASDAQ: IVF F E R T IL IT Y C E N T E R S 1 0 0 0 + C Y C L E S IN 2 0 2 5 A C R O S S 4 F E R T IL IT Y C E N T E R S LO C A T IO N Middleton, WI Atlanta, GA Birmingham, AL Indianapolis, IN1 PRO C E D U RE S IVF, IVC planned IVC, IVF planned IVF and IVC IVF and IVC A N N U A L C Y C LE S ~500 ~150
Slide 10: Wisconsin Fertility Institute – Case Study, M&A Strategy
NASDAQ: IVF CASE STUDY – M&A STRATEGY W IS C O N S IN F E R T IL IT Y IN S T IT U T E A c q uisitio n D e tails • One of Wisconsin’s leading fertility centers (rated top-100 in US by Newsweek) • 5,000+ babies born since 2007, averaged 500+ IVF cycles/year over the last 5 years • Strong team in place
Slide 11: Why Clinics Join INVO Fertility
NASDAQ: IVF ADVAN TAG ES W H Y C L IN IC S J O IN IN V O F E R T IL IT Y L ike -M ind e d Partne rs; S yne rg ie s • Focus on medical practice and patient services, while INVO corporate provides centralized administration, finance, marketing, human resources and other services • Strength in unity –
Slide 12: Technology
N A S D A Q : IV F T E C H N O LO G Y
Slide 13: Leveraging Technology to Expand Access
NASDAQ: IVF L E V E R A G IN G T E C H N O LO G Y T O E X PA N D A C C E S S M e d ic a l d e v ic e he rita g e Unique INVOcell-enabled IVC procedure improves lab efficiency and capacity, increases fertility service supply and helps to reduce the risk of mix- up occurrences, while providing a more
Slide 14: INVOcell: Unique Product, Revolutionary Procedure
NASDAQ: IVF IN V O c e ll® U N IQ U E P R O D U C T , R E V O LU T IO N A R Y P R O C E D U R E For clinical pregnancy rates, INVOcell outcomes are comparable to IVF and more effective than IUI. A D VA N C E D T RE AT M E N T IU I IN V O c e ll (IV C ) IV F 8-10%* ~57.1%** ~51.8%** SUCCESS SUCCESS S
Slide 15: Financials
‘OINVO fel a ;
Slide 16: Revenue & Adjusted EBITDA
NASDAQ: IVF R E V E N U E & A D J U S T E D E B IT D A C O N S O L ID A T E D R E V E N U E ($ M illio ns) A D JU S T E D E B IT D A ($ M illio ns) $8 $0 $6.8 ($1) $7 $6.5 ($2) $6 ($2.2) ($3) $5 ($3.2) ($4) $4 ($5) $3.0 $3 ($5.1) ($6) $2 ($7) $1 $0.8 ($8) ($9) ($8.4) $0 2022 2023 2024 2025 2022 2023
Slide 17: Balance Sheet Highlights
NASDAQ: IVF B A L A N C E S H E E T H IG H L IG H T S ($ USD) 12/31/2023 12/31/2024 12/31/2025 January 2026 - Entered into $7.5 Million Cash and cash equivalents 232,424 619,520 2,077,842 Warrant Inducement Priced At-the- Market Under Nasdaq Rules Other current assets 1,027,351 637,038 683,661 Lease
Slide 18: Cap Structure
NASDAQ: IVF CA P STRUCTURE Data as of 6/12/26 Market capitalization $2.6 M Stock price $1.48 Common shares issued and outstanding 1.786 M Warrants outstanding 2.05 M at Avg. of $12.99 (~1.9 mil @ $7.95) Options, etc outstanding 0.009 M at Avg. $578.86 Conversion of debt and preferred (if converted)
Slide 19: Summary
O)INVvO kertiity NASDAQ: IVF SUMMARY
Slide 20: Why Invest in INVO Fertility? Key Takeaways
N A S D A Q : IV F W H Y IN V E S T IN IN V O F E R T IL IT Y ? KEY TA KEA W AY S G ro w ing C linic M & A Fo c us to D rive Inte g ratio n o f U niq ue Ind ustry M o m e ntum B uild ing O p e ratio ns A d d e d G ro w th Te c hno lo g ie s Tailw ind s To w ard s B re ake ve n • 4 current fully • Pr
Slide 21: People
N A S D A Q : IV F PE O PLE
Slide 22: Experienced & Dedicated Leadership Team
NASDAQ: IVF L E A D E R S H IP T E A M E X P E R IE N C E D & D E D IC A T E D D o c to rs S te ve S hum CEO G re tc he n C o llins S ue E lle n C a rp e nte r N ic k C ata ld o Ja m e s D o na hue 1 A nd re a G o re n Te ra h K rig svo ld M&A/Legal Finance/Accounting L a b D ire c to rs A p ril M c
Slide 23: Board of Directors: Independent & Engaged
NASDAQ: IVF B O A R D O F D IR E C T O R S IN D E P E N D E N T & E N G A G E D S te ve S hum Tre nt D avis R e b e c c a M e ssina B arb ara R yan M atthe w S z o t CEO, Director Independent Director Independent Director Independent Director Independent Director June 2026 © 2026 INVO Fertility, Inc
Slide 24: Thank You
THANK YO U Fo r m o re info rm atio n, p le ase c o ntac t: Steve Shum 978-878-9505 x506 [email protected]
Slide 25: Appendix
N A S D A Q : IV F A P P E N D IX
Slide 26: Income Statement Highlights
NASDAQ: IVF IN C O M E S T A T E M E N T H IG H L IG H T S ($ USD) FY 2022 FY 2023 FY 2024 FY 2025 Clinic 614,854 2,862,574 6,450,431 6,721,057 Product 207,342 158,001 81,569 120,193 Revenue 822,196 3,020,575 6,532,000 6,841,250 Opex 11,448,677 9,787,730 13,159,713 14,078,606 Op loss (10,626,481) (6
Slide 27: Adjusted EBITDA
NASDAQ: IVF A D J U S T E D E B IT D A ($ U S D ) FY 2022 FY 2023 FY 2024 FY 2025 N e t lo ss fro m c o ntinuing o p e ra tio ns (1 0 ,8 9 2 ,5 1 1 ) (8 ,0 3 4 ,6 1 2 ) (7 ,7 3 9 ,9 5 3 ) (5 ,3 3 5 ,9 7 5 ) Interest expense 7,109 205,781 412,860 119,095 Amortization of debt discount 52,644 720,128 6